[Sinovac Biotech's introduced product, BrPac-1 Paclitaxel, has been approved for marketing in Peru] Recently, Sinovac Biotech and Haichang Biotech's joint venture, Paclitaxel for Injection (Albumin-bound) (trade name: Apexelsin®), has been officially approved for marketing by the Peruvian Medical Supplies and Drug Administration (DIGEMID), marking another milestone in its globalization. Currently, BrPac-1 Paclitaxel has completed preparations for shipment to many European countries, and its production capacity can meet domestic and foreign demand simultaneously. The approval in Peru will further expand the coverage of BrPac-1 Paclitaxel in the global pharmaceutical market, and its overseas sales prospects are worth looking forward to.
